Still no cause for alarm

PUBLIC media speculation has continued to raise concerns about the side-effects of Mefloquine (Larium), an anti-malaria drug approved by the World Health Organisation (WHO) that has been used by a number of Australian Army personnel.

The ADF has already taken a conservative approach to the drug’s use following concerns raised over its side-effect profile by the US Department of Defense.

Mefloquine is approved by the Australian Therapeutic Goods Administration, and remains the main anti-malarial medication prescribed by civilian travel medicine clinics for the Australian public travelling to malarious areas.

The WHO recommends Mefloquine as first line prophylaxis against malaria for several countries, including parts of Africa.
It is popular because it’s taken once a week, unlike Doxycycline, which requires daily use.

The Army Malaria Institute conducted research on Mefloquine, which included its use by battalions deployed to East Timor.
Doxycycline remains the preferred prophylaxis for malaria in the ADF, with Mefloquine only prescribed to ADF members unable to tolerate Doxycycline.

These members undergo assessment with a loading dose to determine response to the medication before deployment.
ADF members with any concerns about use of Mefloquine are encouraged to discuss the matter with their medical officer.

A front-page story about the ADF’s use of Mefloquine appeared in the July 15 edition of Army. This can be accessed at http://www.defence.gov.au/news/armynews/editions/1101/topstories/story01.htm